TITLE

Combining angiotensin-receptor blockers with angiotensinconverting- enzyme inhibitors

AUTHOR(S)
Phillips, Christopher O.
PUB. DATE
April 2011
SOURCE
CMAJ: Canadian Medical Association Journal;4/5/2011, Vol. 183 Issue 6, pE309
SOURCE TYPE
Academic Journal
DOC. TYPE
Opinion
ABSTRACT
In this article, the author discusses the study of F. A. McAlister and colleagues regarding the use of the combination of angiotensin-receptor blockers and converting-enzyme inhibitors in the treatment of patients with heart failure. He is critical to the strength of the study, which according to him, is its consistency in terms of adverse drug effects as reported in clinical trials. He also mentions several clinical trials that affirm that the combination lessens morbidity.
ACCESSION #
60159834

 

Related Articles

  • Physicians again rebuked for under use of beta-blockers in heart failure therapy.  // Medical Marketing & Media;Apr2000, Vol. 35 Issue 4, p18 

    Focuses on the use of beta-blockers in heart failure therapy in the United States. Benefits of beta-blocker therapy; `Journal of the American Medical Association' editorial on beta-blocker therapy; Analysis of outcomes from chronic heart failure patients in 14 countries.

  • Post-MI congestive heart failure.  // Modern Medicine;Oct95, Vol. 63 Issue 10, p27 

    Reports on the use of Hoechst-Roussel Pharmaceuticals Inc.'s angiotensin converting enzyme (ACE) inhibitor ramipril for the treatment of stable patients with clinical signs of congestive heart failure (CHF). Dosage; Use of the ramipril within the first few days after an acute myocardial infarction.

  • ACE inhibitors in heart failure.  // American Family Physician;9/15/94, Vol. 50 Issue 4, p844 

    Discusses an article in the January 1994 issue of the periodical `The Practitioner' on the use of angiotensin converting enzyme (ACE) inhibitor in therapy for patients with heart failure. Considerations for physicians before using ACE inhibitors; Guidelines in monitoring treatment.

  • Treatment of Isolated Systolic Hypertension: A Comparative Study of Felodipine, Ramipril and Isosorbide Mononitrate in 1041 Patients. Lohmann, F.W. // Clinical Drug Investigation;1999, Vol. 18 Issue 3, p173 

    Background: A loss of elasticity of the aortic arch and major arteries near the heart, with acceleration of the pulse wave and amplification of this effect in the periphery, leads to isolated systolic arterial hypertension (ISH). According to experimental and clinical data, dihydropyridine-type...

  • The Pressure's On. Smith, Ian K. // Time International (South Pacific Edition);9/11/2000, Issue 36, p78 

    Analyzes various drugs which treat hypertension and offers alternatives to calcium channel blockers, which have been shown to contribute to heart trouble. The treatment value of diuretics; The safety record of beta blockers; Evaluation of ACE inhibitors; How Alpha-blockers work; Other...

  • The Pressure's On. Smith, Ian K. // Time;9/11/2000, Vol. 156 Issue 11, p126 

    Analyzes various drugs which treat hypertension and offers alternatives to calcium channel blockers, which have been shown to contribute to heart trouble. The treatment value of diuretics; The safety record of beta blockers; Evaluation of ACE inhibitors; How Alpha-blockers work; Other...

  • Calcium Sensitising Agents in Heart Failure. Mathew, L.; Katz, S.D. // Drugs & Aging;1998, Vol. 12 Issue 3, p191 

    Congestive heart failure (CHF) is a common cardiovascular disorder that is characterised, in part, by a decreased cardiac output reserve. Accordingly, there is ongoing interest in the role of positive inotropic agents (e.g. adrenergic agonists and phosphodiesterase type III inhibitors, which...

  • Renin-Angiotensin-Aldosterone System Inhibitors in Heart Failure. Shearer, F; Lang, C C; Struthers, A D // Clinical Pharmacology & Therapeutics;Oct2013, Vol. 94 Issue 4, p459 

    Heart failure (HF) is a very common condition that, despite advances in treatment, carries significant morbidity and mortality. Although there is good evidence for the treatment of HF with reduced ejection fraction (HFrEF), the treatment for HF with preserved ejection fraction (HFpEF) is not...

  • Phase I Trial Design for Solid Tumor Studies of Targeted, Non-Cytotoxic Agents: Theory and Practice. Parulekar, Wendy R.; Eisenhauer, Elizabeth A. // JNCI: Journal of the National Cancer Institute;7/7/2004, Vol. 96 Issue 13, p990 

    Background: New targeted, non-cytotoxic anticancer agents, such as small-molecule kinase inhibitors, pose challenges to the current phase I paradigm of dose selection based on toxicity. Moreover, increasing the drug dose to toxicity may be unnecessary for drug effect, making the use of maximum...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics